Holen Sie sich die Stockscreener-App
1.16
1.69%
-0.02
Handel nachbörslich:
1.19
0.03
+2.59%
Schlusskurs vom Vortag:
$1.18
Offen:
$1.2
24-Stunden-Volumen:
472.04K
Relative Volume:
0.97
Marktkapitalisierung:
$71.83M
Einnahmen:
$248.00K
Nettoeinkommen (Verlust:
$-113.22M
KGV:
-0.6299
EPS:
-1.8416
Netto-Cashflow:
$-98.81M
1W Leistung:
+1.75%
1M Leistung:
-1.69%
6M Leistung:
-4.13%
1J Leistung:
-11.45%
1-Tages-Spanne:
$1.14
$1.20
1-Wochen-Bereich:
$1.12
$1.20
52-Wochen-Spanne:
$1.09
$1.95
Pliant Therapeutics Inc Stock (PLRX) Company Profile
Firmenname
Pliant Therapeutics Inc
Sektor
Branche
Telefon
650-481-6770
Adresse
331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Compare PLRX vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PLRX
Pliant Therapeutics Inc
|
1.16 | 71.83M | 248.00K | -113.22M | -98.81M | -1.8416 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Pliant Therapeutics Inc Stock (PLRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-10 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2025-03-04 | Fortgesetzt | Cantor Fitzgerald | Neutral |
| 2025-03-04 | Herabstufung | Needham | Buy → Hold |
| 2025-03-03 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-03-03 | Herabstufung | Stifel | Buy → Hold |
| 2025-02-10 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2025-02-10 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-02-10 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-02-10 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-02-10 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2025-02-10 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-10 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-09-09 | Fortgesetzt | Leerink Partners | Outperform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-05-18 | Eingeleitet | Canaccord Genuity | Buy |
| 2023-04-13 | Eingeleitet | Robert W. Baird | Outperform |
| 2022-12-14 | Eingeleitet | Stifel | Buy |
| 2022-12-07 | Eingeleitet | JP Morgan | Overweight |
| 2022-09-01 | Eingeleitet | Citigroup | Buy |
| 2022-07-20 | Eingeleitet | SVB Leerink | Outperform |
| 2022-05-25 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-12-10 | Eingeleitet | Oppenheimer | Outperform |
| 2021-11-24 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-11-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-04-20 | Eingeleitet | BTIG Research | Buy |
| 2021-04-05 | Eingeleitet | Citigroup | Buy |
| 2020-06-29 | Eingeleitet | Citigroup | Buy |
| 2020-06-29 | Eingeleitet | Cowen | Outperform |
| 2020-06-29 | Eingeleitet | Needham | Buy |
| 2020-06-29 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Pliant Therapeutics Inc Aktie (PLRX) Neueste Nachrichten
Pliant Therapeutics Inc (PLRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Pliant Therapeutics Inc (PLRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Pliant Therapeutics Inc (PLRX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Pliant Therapeutics Inc (PLRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Pliant Therapeutics Inc (PLRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Pliant Therapeutics Inc (PLRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Pliant Therapeutics Inc (PLRX) Institutional Confidence - TradingKey
Pliant Therapeutics Inc (PLRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Pliant Therapeutics (PLRX) director receives 70,000 stock options at $1.14 - Stock Titan
Pliant Therapeutics (PLRX) director granted 70,000 options at $1.14 strike - Stock Titan
Pliant Therapeutics (PLRX) director receives 70,000-share stock option grant - Stock Titan
Pliant (NASDAQ: PLRX) director awarded 70,000 stock options at $1.14 - Stock Titan
PLIANT THERAPEUTICS (PLRX) director granted 70,000 stock options at $1.14 - Stock Titan
Director Darren Cline receives 70,000 PLRX stock options at $1.14 strike price - Stock Titan
Pliant Therapeutics Shareholders Approve Directors and Executive Pay - TipRanks
Pliant Therapeutics (NASDAQ: PLRX) reports 2026 director, pay and auditor votes - Stock Titan
PLIANT THERAPEUTICS INC (PLRX) Stock Chart - ChartMill
Pliant Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference - The Manila Times
Primary Sclerosing Cholangitis Market is Projected to Boom by 2034 Owing to the Launch of Novel Therapies | DelveInsight - Barchart
Pliant Therapeutics (PLRX) Inches Higher: Consolidation Near Support Amid Biotech Sector VolatilityAccumulation Line - newsline.com
Pliant Therapeutics (PLRX) Holds Near Support Amid Modest Gains, Biotech Sector Weakness PersistsNAAIM Leverage - The Legal Advocate
Pliant Therapeutics Rises $1.25 Ahead of ASCO Conference - Bez Kabli
Pliant Therapeutics (PLRX) Holds Near Support Amid Modest Gains – Key Levels in FocusCumulative Volume - The Legal Advocate
Pliant Therapeutics (PLRX) Edges Higher as Stock Holds Above Key SupportNHNL Ratio - The Legal Advocate
Pliant Therapeutics (PLRX) Faces Selling Pressure, Testing Key Support at $1.15Revenue Growth Stocks - newsline.com
Pliant Therapeutics to present Phase 1b trial data of PLN-101095 at ASCO 2026. - Pluang
Pliant Therapeutics (PLRX) Bounces 2.5% as Biotech Tests Key ResistanceStock Idea Network - newser.com
Global oncology researchers to review FORTIFY data as Pliant Therapeutics joins ASCO meeting - Traders Union
Pliant Drug Aims to Break Cancer's Resistance to Immunotherapy - BriefGlance
Pliant Therapeutics (PLRX) Q1 2026 Earnings Beat: Revenue $N/A, EPS $-0.32Crowd Entry Signals - newser.com
Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical ... - Caledonian Record
Pliant Therapeutics Announces Upcoming Presentation at the - GlobeNewswire
Phase 1 cancer trial pairs oral integrin inhibitor with pembrolizumab - Stock Titan
Pliant Therapeutics (PLRX) Stock: Consolidating at $1.20 — Next Move Ahead 2026-05-21Equity Put Call - Newser
Pliant Therapeutics Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Pliant Therapeutics (PLRX) Delivers Q1 2026 Beat — EPS $-0.32 vs $-0.36 ExpectedEPS Guidance Update - The Legal Advocate
Australian biotech advancing pulmonary program adds Pliant CEO as chair - Stock Titan
Pliant Therapeutics (PLRX) Stock Price, Quote, Charts & News - Invezz
Atisama Therapeutics Advances RB042 into Multiple Ascending Dose cohorts of Phase 1 Trial and Appoints Bernard Coulie as Chair of the Board – Company AnnouncementFT.com - Financial Times
TradingKey - TradingKey
Oppenheimer Sticks to Its Hold Rating for Pliant Therapeutics (PLRX) - The Globe and Mail
Number of shareholders of Pliant Therapeutics, Inc. – MUN:9PT - TradingView
CCORF Downgrades Pliant Therapeutics(PLRX.US) to Hold Rating, Maintains Target Price $3 - Moomoo
A Quick Look at Today's Ratings for Pliant Therapeutics(PLRX.US), With a Forecast Between $2 to $3 - Moomoo
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results - markets.businessinsider.com
Pliant Therapeutics (PLRX) Advances Clinical Trials and Pipeline Development - GuruFocus
Pliant Therapeutics Q1 net loss narrows on lower expenses - TradingView
Pliant Therapeutics (NASDAQ: PLRX) cuts Q1 2026 net loss to $20M - Stock Titan
Pliant Therapeutics (PLRX) narrows Q1 2026 loss as PLN-101095 shows early responses - Stock Titan
Pliant Therapeutics (NASDAQ:PLRX) Stock Rating Lowered by Wall Street Zen - MarketBeat
PLRX (Pliant Therapeutics) quarterly loss narrower than feared; shares tick up as pipeline hopes support sentiment.Margin Improvement - newser.com
Finanzdaten der Pliant Therapeutics Inc-Aktie (PLRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.74%
1.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):